Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 7/20 | 0.38 |
| ▸ | CNR2 | P34972 | 6/20 | 0.38 |
| ▸ | CALCA | P06881 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CD38 | P28907 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20001854 | 1.00 | LMNA (0.39) | LMNAL3MBTL1CNR1CNR2CALCA | |
| SCHEMBL20002546 | 0.98 | LMNA (0.41) | LMNAL3MBTL1CNR1CNR2CALCA | |
| SCHEMBL20002241 | 0.96 | CD38 (0.38) | LMNAL3MBTL1CNR1CNR2CALCA | |
| SCHEMBL20042318 | 0.96 | CD38 (0.38) | LMNAL3MBTL1CNR1CNR2CALCA | |
| SCHEMBL20002611 | 0.93 | CD38 (0.36) | LMNAL3MBTL1CNR1CNR2CALCA | |
| SCHEMBL20002349 | 0.93 | CALCA (0.37) | LMNAL3MBTL1CNR1CNR2CALCA | |
| SCHEMBL20002350 | 0.92 | CNR2 (0.40) | LMNAL3MBTL1CNR2CALCACD38 | |
| SCHEMBL20002677 | 0.91 | CALCA (0.34) | LMNAL3MBTL1CNR1CNR2CALCA | |
| SCHEMBL20042331 | 0.91 | CD38 (0.36) | CNR1CALCACD38CYP3A4 | |
| SCHEMBL20002123 | 0.91 | CD38 (0.37) | LMNAL3MBTL1CALCACD38CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2018057973-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | IDO1, TDO2, IDO2 | LMNA 4252/4885L3MBTL1 2523/4885CNR1 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.